

1 **SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against** 2 **SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody** 3 **concentrations in serological assays**

4
5 Alina Seidel, MSc*¹; Bernd Jahrsdörfer, MD*²; Sixten Körper, MD*²; Dan Albers MSc¹; Pascal von Maltitz,
6 MSc¹; Rebecca Müller, MD³; Ramin Lotfi, MD²; Patrick Wuchter, MD³; Harald Klüter, MD.³; Michael
7 Schmidt, MD⁴; Jan Münch, PhD^{1§}; Hubert Schrezenmeier, MD^{2§}

8
9 ¹ Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, German

10 ² German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, Institute and Institute for Clinical
11 Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-
12 Württemberg-Hessen and University Hospital Ulm; and Institute of Transfusion Medicine, University of Ulm

13 ³ Institute of Transfusion and Immunology, German Red Cross Blood Transfusion Service Baden-
14 Württemberg - Hessen, Medical Faculty Mannheim, Heidelberg University, Mannheim

15 ⁴ Institute of Transfusion Medicine and Immunohematology, German Red Cross Blood Transfusion Service Baden-
16 Württemberg – Hessen, Frankfurt, Germany

17
18 *equally contributed to this manuscript.

19 § equally contributing senior authors

20
21 **Short title: Neutralization of SARS-CoV-2 Omicron by sera from vaccinated convalescents**

22 Word Counts:

23 Abstract: 265 words

24 Manuscript text: 1417 words (without abstract, legends and references)

25 1 Table

26 4 Figures

27 28 **Corresponding address:**

29 *Prof.Dr.med.Hubert Schrezenmeier,*

30 *German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and Institute for Clinical*
31 *Transfusion Medicine and Immunogenetics Ulm; and Institute of Transfusion Medicine, University of Ulm.*
32 *Helmholtzstraße 10, 89081 Ulm, Germany.*

33 h.schrezenmeier@blutspende.de

34 *phone: +49 731 150 550*

35 *Fax: +49 731 150 500*

36 **ABSTRACT:**

37 **Background:**

38 Recent data on immune evasion of new SARS-CoV-2 variants raise concerns about antibody-based COVID-
39 19 therapies. Therefore in this study the *in-vitro* neutralization capacity against SARS-CoV-2 variants
40 Wuhan D614G, Delta and Omicron in sera of convalescent individuals with and without boost by
41 vaccination was assessed.

42 **Methods and Findings:**

43 This *in-vitro* study included 66 individuals with a history of SARS-CoV-2 infection, divided into subgroups
44 without (n=29) and with SARS-CoV-2 vaccination (n=37). We measured SARS-CoV-2 antibody
45 concentrations by serological assays (anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and Elecsys Anti-SARS-CoV-
46 2 S) and neutralizing titers against Wuhan D614G, Delta and Omicron in a pseudovirus neutralization
47 assay.

48 Sera of the majority of unvaccinated convalescents did not effectively neutralize Delta and Omicron (4/29,
49 13.8% and 19/29, 65.5%, resp.). Neutralizing titers against Wuhan D614G, Delta and Omicron were
50 significantly higher in vaccinated compared to unvaccinated convalescents ($p < 0.0001$) with 11.1, 15.3 and
51 60-fold higher geometric mean of 50%-neutralizing titers (NT50) in vaccinated compared to unvaccinated
52 convalescents. The increase in neutralizing titers was already achieved by one vaccination dose.
53 Neutralizing titers were highest in the first 3 months after vaccination. Concentrations of anti-S antibodies
54 in the serological assays anti-SARS-CoV-2 QuantiVac-ELISA (IgG) and Elecsys Anti-SARS-CoV-2 S predict
55 neutralization capacity against Wuhan D614G, Delta and Omicron. While Wuhan D614G was neutralized
56 *in-vitro* by Bamlanivimab, Casirivimab and Imdevimab, Omicron was resistant to these monoclonal
57 antibodies.

58 **Conclusions:**

59 These findings confirm substantial immune evasion of Delta and Omicron which can be overcome by
60 vaccination of convalescents. This informs strategies for choosing of plasma donors in COVID-19
61 convalescent plasma programs that shall select specifically vaccinated convalescents with very high titers
62 of anti-S antibodies.

63 **Introduction:**

64 The B.1.1.529 variant was first reported to the World Health Organization from South Africa on 24
65 November 2021 (1) and has been classified as a variant of concern (VOC), named Omicron (1).

66 The role of passive immune therapy of COVID-19 by convalescent plasma (CCP) is still under investigation.
67 Data suggest efficacy of CCP in early intervention (2-6), in particular among seronegative patients and
68 immunosuppressed patients (7-9). A significant antibody dose response has been observed in some of the
69 CCP trials (3;4;10;11). Omicron might escape passive immune therapy since it can evade neutralization by
70 sera from vaccinated and convalescent individuals and by monoclonal antibodies *in-vitro* (12-16) and the
71 risk of reinfection with Omicron is higher compared to other VOC (12).

72 In this study, we assessed the neutralization capacity of sera from convalescents, some but not all of which
73 were vaccinated, against the Wuhan D614G, Delta and Omicron variants. The question was whether
74 superimmunized individuals, i.e. vaccinated convalescents, had cross-neutralization capacity against
75 Omicron sufficient to be considered as plasma donors for passive immune therapy.

76 **Methods:**

77 Serum samples from 66 individuals with SARS-CoV-2 infection (with or without SARS-CoV-2 vaccination)
78 were analyzed by two commercially available assays according to the instructions of the manufacturer
79 (anti-SARS-CoV-2-QuantiVac-ELISA (IgG), Euroimmun, Lübeck, Germany and Elecsys Anti-SARS-CoV-2 A,
80 Roche, Mannheim, Germany). Samples were collected after informed consent from convalescent plasma
81 donors (17) and vaccinees. The studies were approved by the Ethical Committee of University of Ulm and
82 Ethical Committee II, Heidelberg University.

83 **Preparation of pseudotyped particles**

84 Production of rhabdoviral pseudotypes has been previously described (18). In brief, 293T cells (ATCC no.
85 CRL-3216) were transfected with expression plasmids encoding SARS-CoV-2 spike variants Wuhan D614G
86 (<https://doi.org/10.1016/j.cell.2021.03.036>), B.1.617.2 (<https://doi.org/10.1126/science.abh1766>), or
87 B.1.1.529 (<https://doi.org/10.1101/2021.12.12.472286>) (kindly provided by Stefan Pöhlmann, Infection
88 Biology Unit, German Primate Center, Göttingen, Germany) by Transit LT-1 (Mirus). One day after
89 transfection, cells were inoculated with a replication-deficient vesicular stomatitis virus (VSV) vector in
90 which the genetic information for its native glycoprotein (VSV-G) is replaced by genes encoding enhanced
91 green fluorescent protein and firefly luciferase (FLuc) (kindly provided by Gert Zimmer, Institute of
92 Virology and Immunology, Mittelhäusern, Switzerland), and incubated for 2 h at 37°C. Then the inoculum
93 was removed, cells were washed with PBS and fresh medium containing anti-VSV-G antibody (I1-
94 hybridoma cells; ATCC no. CRL-2700) added to block remaining VSV-G carrying particles. After 16-18 h,
95 supernatants were collected and centrifuged (2,000 x g, 10 min, room temperature) to clear cellular
96 debris. Samples were then aliquoted and stored at -80°C.

97 **Pseudovirus Neutralization Assay:**

98 The pseudovirus neutralization experiments were performed as previously described (18) In brief, Vero
99 E6 cells were seeded in 96-well plates one day prior (6,000 cells/well, 2.5% FCS. Heat-inactivated (56°C,
100 30 min) sera were serially titrated (4-fold titration series with 7 steps + buffer only control) in PBS,

101 pseudovirus stocks added (1:1, v/v) and the mixtures incubated for 30 min at 37°C before being added to
102 cells in duplicates (final on-cell dilution of sera: 20, 80, 320, 1,280, 5,120, 20,480, 81,920-fold). After an
103 incubation period of 16-18 h, transduction efficiency was analyzed. For this, the supernatant was
104 removed, and cells were lysed by incubation with Cell Culture Lysis Reagent (Promega) at room
105 temperature. Lysates were then transferred into white 96-well plates and luciferase activity was
106 measured using a commercially available substrate (Luciferase Assay System, Promega) and a plate
107 luminometer (Orion II Microplate Luminometer, Berthold). For analysis of raw values (RLU/s), background
108 signal of untreated cells was subtracted and values normalized to cells inoculated with pseudovirus
109 preincubated with PBS only. Results are given as serum dilution on cell resulting in 50% pseudovirus
110 neutralization (NT50), calculated by nonlinear regression ([Inhibitor] vs. normalized response – Variable
111 slope) in GraphPad Prism Version 9.1.1. For quantitative analyses, NT50 values <20 were set to a value of
112 10.

113 The other statistical analyses were performed using GraphPad Prism Version 9.0.2, GraphPad Software,
114 San Diego, California USA, www.graphpad.com and NCSS 2021 Statistical Software (2021). NCSS, LLC.
115 Kaysville, Utah, USA, ncss.com/software/ncss.

116 **Results:**

117 We studied a cohort of 66 individuals with a history of a SARS-CoV-2 infection (Table 1). The cohort has
118 been subdivided in a group without vaccination (n=29) and a group with vaccination (n=37).

119 Non-vaccinated individuals with a history of infection exhibited Wuhan D614G neutralizing titers of 249
120 (geometric mean neutralizing (GMN) titers, 95% confidence interval (95%-CI) 162-381) (Fig.1A).
121 Neutralization of Delta and Omicron was undetectable (i.e. below a titer of 20) in 4/29 (13.8%) and 19/29
122 (65.5%) of convalescent individuals with GMN titers of 55 (35-88) and 20 (13-32)(p=0.0021 compared to
123 Wuhan D614G). However, convalescents who had received at least one vaccination dose exhibited
124 significantly higher neutralizing titers compared to non-vaccinated convalescents: 2761 (1763-4323)
125 against Wuhan D614G, 841 (545-1300) against Delta and 1204 (634-2284) against Omicron (Fig.1A). Fold-
126 difference in GMN titers of vaccinated convalescents versus non-vaccinated convalescents is 11.1-fold for
127 Wuhan D614G, 15.3-fold for Delta and 60-fold for Omicron (Fig.1A). Neutralizing titers against Wuhan
128 D614G and Omicron did no longer differ significantly in convalescents after vaccination (Fig.1A). For all
129 three variants, neutralizing titers were not significantly different between subjects who received either
130 one or two vaccinations, resp. (Fig.1B). Neutralizing titers against Wuhan D614G and Delta were
131 significantly higher among those with an interval ≤ 90 days since the last vaccination dose as compared to
132 intervals >90 days, while for Omicron no such significant difference was found (Fig.1C). The geometric
133 means of NT50 against Wuhan D614G were 4741 (≤ 90 days) and 1644 (>90 days)(p=0.0326), against Delta
134 1496 (≤ 90 days)) and 501 (>90 days)(p=0.0202), and against Omicron 1953 (≤ 90 days)) and 843 (>90
135 days)(p=0.1352). While in the pseudovirus neutralization assay Omicron was neutralized *in-vitro* by the
136 polyvalent antibodies of convalescent, vaccinated individuals (Fig.1A), it was resistant to the monoclonal
137 antibodies Bamlanivimab, Casirivimab and Imdevimab (Fig.1D).

138 The correlation matrix of NT50 against Wuhan D614G, Delta and Omicron, the –QuantiVac-ELISA (IgG)
139 ELISA and the Elecsys Anti-SARS-CoV-2 S revealed good correlations between all five assays, in particular
140 between the two anti-SARS-CoV-2 serological assays (Spearman correlation 0.95) and the NT50 against
141 Wuhan D614G and Delta (Spearman correlation 0.93)(Fig.2). Spearman correlation between anti-SARS-

142 CoV-2-QuantiVac-ELISA (IgG) and NT50 against Omicron or Delta was 0.88 and 0.94 (Fig.3A and Fig.3C).
143 The Spearman correlation between Elecsys Anti-SARS-CoV-2 S and NT50 against Omicron and Delta was
144 0.92 and 0.90 (Fig.3B and Fig.3D).
145 Plasma units for immune therapy shall have very high neutralizing titers - we assumed $NT50 \geq 640$. Receiver
146 operating characteristics (ROC) demonstrate that both anti-SARS-CoV-2-QuantiVac-ELISA- (IgG) and
147 Elecsys anti-SARS-CoV-2 S excellently predict these neutralizing titers with areas under the curve between
148 0.94 and 0.95 for anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and between 0.95 and 0.98 for Elecsys Anti-
149 SARS-CoV-2 S (Fig.4A-C).

150 **Discussion**

151 Our observations are consistent with other *in-vitro* studies which reported significant immune evasion by
152 Omicron (12;13;15;16). This has raised concerns that antibody therapies may no longer be effective
153 against Omicron.

154 Therefore, in contrast to other recent studies on Omicron immune evasion, we focus on convalescent
155 individuals and the implication of evasion from antibody-mediated neutralization for future CCP
156 programs. Our data confirm *in-vitro* resistance of Omicron to several monoclonal antibodies used in
157 clinical practice (13-16) questioning the efficacy in Omicron infected patients. Also, Delta and Omicron
158 are no longer well neutralized *in-vitro* by sera of convalescents from the first and second surge of the
159 SARS-CoV-2 pandemic. However, in convalescents just one dose of SARS-CoV-2 vaccination can restore
160 *in-vitro* neutralization capacity against Delta and Omicron. In contrast to other recent reports on
161 significantly lower neutralization capacity in vaccinated convalescent donors (14-16) compared to wild
162 type, we observed a comparable neutralization capacity against Wuhan D614G and Omicron. This might
163 be due to our high sample size, the neutralization assay, the large proportion of donors with high anti-S
164 antibody concentration in our cohort and the vaccination scheme. Our findings suggest that even without
165 adaption of current available vaccines, the broader immune repertoire in superimmunized individuals can
166 cover novel variants (19), particularly in the first three months after vaccination when the highest
167 neutralizing titers are achieved.

168 Systematic screening of convalescent, vaccinated donors using commercially available high-throughput
169 serological assays (Anti-SARS-CoV-2-QuantiVac-ELISA (IgG); Elecsys Anti-SARS-CoV-2 S) can identify
170 plasma donors with very high SARS-CoV-2 antibody concentrations, who also have very high *in-vitro*
171 neutralizing titers against Wuhan D614G, Delta and Omicron. Therefore, for future convalescent plasma
172 programs, priority should be given to superimmunized donors with previous infection plus at least one
173 dose of a SARS-CoV-2 vaccination (preferably within the last 3 months) with very high SARS-CoV-2
174 antibody concentrations as measured by serological assays. A concept of early, very high titer CCP from

175 highly selected superimmunized donors must be investigated in clinical trials (e.g. COVIC-19 trial, EudraCT
176 021-006621-22).

177 **Conflicts of interest:**

178 B.J., S.K., R.L., R.M., P.W., M.S., H.K. and H.S. are employees of a blood transfusion service collecting
179 plasma including convalescent plasma.

180

181 **Acknowledgement:**


182 The clinical trials COVIC-19 (EudraCT 021-006621-22) is supported by the Bundesministerium für Bildung
183 und Forschung (“German Federal Ministry of Education and Research”) and the randomized clinical trial
184 CAPSID (EudraCT including the preparation of convalescent plasma units was supported by the
185 Bundesministerium für Gesundheit (“German Federal Ministry of Health”). H.S., J.M. and H.K.
186 acknowledge funding from the Ministry for Science, Research and the Arts of Baden-Württemberg,
187 Germany (COVID-19 Sonderförderlinie, CORE Project). HS acknowledges funding by the European
188 Commission (HORIZON2020 Project SUPPORT-E, no. 101015756). J.M. further acknowledges funding by
189 EU’s Horizon 2020 research and innovation programme (Fight-nCoV, 101003555).

190 **Table 1: Characteristics of the study cohort of convalescent individuals**

	Prior history of infection no vaccination (n=29)	Prior history of infection + vaccination (n=37)*
Median age, years (IQR)	48 (34-57)	48.5 (32.8-56)
Gender, no Female / male	13 / 16	26 / 11
Median interval since infection, days (IQR)	119.0 (85.0– 136.5)	387.0 (226.0 – 434.0)
No. of vaccination doses, n (%)		
0	29 (100%)	-
1	-	17 (45.9%)
2	-	20 (54.1%)
Type of vaccination, n (%)	n.a.	
BNT162b		25 (67.6)
mRNA-1273		7 (18.9)
ChAdOx1		5 (13.5)
Median interval since last vaccination	n.a.	93.0 (25.0 – 160.3)

191 n.a.: not applicable

192 * n=3 individuals had breakthrough infection after vaccination.



195 **Figure 1: Neutralization of Spike variants by convalescent sera and monoclonal antibodies**

196 **A)** NT50 for in-vitro neutralization of Wuhan D614G (blue symbols), Delta (green symbols) and Omicron (red symbols) for individuals with a history of
197 infection (inf)(lighter colors)(n=29) and history of infection and vaccination (inf + vax, darker colors)(n=37). The p-values for the pairwise comparisons
198 shown above the graph were calculated by Kruskal-Wallis Test followed by Dunn's test for correction for multiple comparisons. The horizontal black
199 lines denote the geometric mean of NT50 and the error bars the 95%-confidence interval of the geometric mean. Fold-increase in geometric mean NT50
200 of vaccinated convalescents versus non-vaccinated convalescents is 11.1-fold for Wuhan D614G, 15.3-fold for Delta and 60-fold for Omicron.


201 **B)** NT50 for in-vitro neutralization of Wuhan D614G (blue symbols), Delta (green symbols) and Omicron (red symbols) for vaccinated, convalescent donors
202 stratified by number of vaccination doses: 1 vaccination dose (1 vax)(lighter colors)(n=17) and 2 vaccination doses (2 vax)(darker colors)(n=20). The p-
203 values for the pairwise comparisons were calculated by Kruskal-Wallis Test. The horizontal black lines denote the geometric mean of NT50 and the error
204 bars the 95%-confidence interval of the geometric mean. The geometric means of NT50 were as follows: against Wuhan D614G 4102 (1 vax) and 1972
205 (2 vax), against Delta 1038 (1 vax) and .704 (2 vax), against Omicron 160 (1 vax) and 943 (2 vax).

206 **C)** NT50 for in-vitro neutralization of Wuhan D614G (blue symbols), Delta (green symbols) and Omicron (red symbols) for vaccinated, convalescent donors
207 stratified by interval between vaccination and collection of serum sample: ≤ 90 days (lighter colors)(n=17) and >90 days (darker colors)(n=19). The p-
208 values for the pairwise comparisons were calculated by Kruskal-Wallis Test. The horizontal black lines denote the geometric mean of NT50 and the error
209 bars the 95%-confidence interval of the geometric mean. The geometric means of NT50 were as follows: against Wuhan D614G 4741 (≤ 90 days) and
210 1644 (>90 days), against Delta 1496 (≤ 90 days) and 501 (>90 days), against Omicron 1953 (≤ 90 days) and 843 (>90 days).

211 **D)** Inhibition of cell entry of Wuhan D614G (blue symbols), Delta (green symbols) and Omicron (red symbols) spike carrying pseudoparticles by monoclonal
212 antibodies. Increasing doses of Bamlanivimab (triangles), Casirivimab (squares) and Imdevimab (circles) were preincubated with pseudoparticles before
213 addition to cells (doses were titrated in 4-fold dilution from 2000 ng/ml to 0.49 ng/ml (final concentrations on cells)). Infection rates in A-D were
214 determined 16 hours post infection by measuring luciferase activities in cellular lysates. Data shown were derived from one experiment performed in
215 duplicates.

216

Figure 2:




219

220

221 **Figure 2: Correlation of anti-S antibody concentrations and neutralization capacity against spike variants**

222 Correlation matrix of NT50 against Omicron, Wuhan D614G, Delta, and anti-SARS-CoV-2 QuantiVac (IgG) ELISA and Elecsys SARS-CoV-2 based on
223 Spearman Correlation. The dendrogram shows clustering of NT50 against Wuhan D614G and Delta and between anti-SARS-CoV-2-QuantiVac-ELISA (IgG)
224 and Elecsys Anti-SARS-CoV-2 S.


225




230 **Figure 3: Correlation between anti-S antibody concentrations and NT50 against Delta and Omicron**

- 231 **A)** Correlation between anti-S antibody concentrations measured by anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and NT50 against Omicron (Spearman
232 correlation 0.88). Results of non-vaccinated convalescents (inf) are shown as triangles, and results of vaccinated convalescents (inf + vax) are shown as
233 filled circles.
- 234 **B)** Correlation between anti-S antibody concentrations measured by Elecsys Anti-SARS-CoV-2 S and NT50 against Omicron (Spearman correlation 0.92).
235 Results of non-vaccinated convalescents (inf) are shown as triangles, and results of vaccinated convalescents (inf + vax) are shown as filled circles.
- 236 **C)** Correlation between anti-S antibody concentrations measured by anti-SARS-CoV-2 QuantiVac-ELISA (IgG) and NT50 against Delta (Spearman correlation
237 0.94). Results of non-vaccinated convalescents (inf) are shown as triangles, and results of vaccinated convalescents (inf + vax) are shown as filled circles.
- 238 **D)** Correlation between anti-S antibody concentrations measured by Elecsys Anti-SARS-CoV-2 S and NT50 against Delta (Spearman correlation 0.90). Results
239 of non-vaccinated convalescents (inf) are shown as triangles, and results of vaccinated convalescents (inf + vax) are shown as filled circles.


A



B



C



242

243

244 **Figure 4: Receiver operating characteristics analyses of serological assays and neutralization of spike variants**

245 Receiver operating characteristics (ROC) analyses of Elecsys Anti-SARS-CoV-2 S (red lines) and anti-SARS-CoV-2-QuantiVac-ELISA (IgG) (blue lines) prediction of
246 neutralization of Wuhan D614G (panel A), Delta (panel B) and Omicron (panel C). A positive neutralizing titer was arbitrarily defined as ≥ 640 . Area under the
247 curve (AUC) is reported in the graphs, $p < 0.0001$ for all serological assays and all spike variants.

248

Reference List

249

- 250 (1) WHO Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. [https://www.who](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b-1-1-529)-sars-cov-2-variant-of-concern)
251 [int/news/item/26-11-2021-classification-of-omicron-\(b 1 1 529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b-1-1-529)-sars-cov-2-variant-of-concern)
252 2021.
- 253 (2) Libster R, Perez MG, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early High-Titer Plasma
254 Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med* 2021 Feb 18;384(7):610-8.
- 255 (3) Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent Plasma
256 Antibody Levels and the Risk of Death from Covid-19. *N Engl J Med* 2021 Mar 18;384(11):1015-
257 27.
- 258 (4) Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Significantly Decreased
259 Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early
260 with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome
261 Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. *Am J Pathol* 2021 Jan;191(1):90-107.
- 262 (5) Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, et al. Randomized Controlled Trial
263 of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. *medRxiv* 2021 Jan
264 1;<http://medrxiv.org/content/early/2021/12/21/2021.12.10.21267485:2021>.
- 265 (6) de Candia P., Prattichizzo F, Garavelli S, La GR, De RA, Pontarelli A, et al. Effect of time and titer in
266 convalescent plasma therapy for COVID-19. *iScience* 2021 Aug 20;24(8):102898.
- 267 (7) Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, et al. Association
268 of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-
269 19. *JAMA Oncol* 2021 Jun 17;7(8):1167-75.
- 270 (8) Senefeld JW, Klassen SA, Ford SK, Senese KA, Wiggins CC, Bostrom BC, et al. Use of convalescent
271 plasma in COVID-19 patients with immunosuppression. *Transfusion* 2021 May 25;61(8):2503-11.
- 272 (9) Hueso T, Godron AS, Lanoy E, Pacanowski J+, Levi LI, Gras E, et al. Convalescent plasma improves
273 overall survival in patients with B-cell lymphoid malignancies and COVID-19: a longitudinal cohort
274 and propensity score analysis. *medRxiv* 2022 Jan
275 1;<http://medrxiv.org/content/early/2022/01/01/2021.12.29.21268525:2021>.
- 276 (10) Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, et al. Results of the CAPSID
277 randomized trial for high-dose convalescent plasma in patients with severe COVID-19. *J Clin Invest*
278 2021 Oct 15;131: e152264(20).
- 279 (11) O'Donnell MR, Grinsztejn B, Cummings MJ, Justman JE, Lamb MR, Eckhardt CM, et al. A
280 randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19.
281 *J Clin Invest* 2021 Jul 1;131: e150646(13).
- 282 (12) Rössler A, Riepler L, Bante D, Laer Dv, Kimpel J. SARS-CoV-2 B.1.1.529 variant (Omicron) evades
283 neutralization by sera from vaccinated and convalescent individuals. *medRxiv* 2021 Jan
284 1;<http://medrxiv.org/content/early/2021/12/11/2021.12.08.21267491:2021>.
- 285 (13) Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced Neutralization of
286 SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. *medRxiv* 2021 Jan
287 1;<http://medrxiv.org/content/early/2021/12/08/2021.12.07.21267432.1:2021>.

- 288 (14) Liu L, Iketani S, Guo Y, Chan JF-W, Wang M, Liu L, et al. Striking antibody evasion manifested by
289 the Omicron variant of SARS-CoV-2. *Nature* 2021;doi: [https://doi.org/10.1038/d41586-021-](https://doi.org/10.1038/d41586-021-03826-3)
290 [03826-3](https://doi.org/10.1038/d41586-021-03826-3).
- 291 (15) Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Considerable
292 escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature* 2021;doi:
293 <https://doi.org/10.1038/d41586-021-03827-2>.
- 294 (16) Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, et al. Broadly neutralizing
295 antibodies overcome SARS-CoV-2 Omicron antigenic shift. *Nature* 2021;doi:
296 <https://doi.org/10.1038/d41586-021-03826-3>.
- 297 (17) Körper S, Jahrsdörfer B, Corman VM, Pilch J, Wuchter P, Blasczyk R, et al. Donors for SARS-CoV-2
298 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time
299 Course of SARS-CoV-2 Neutralizing Antibodies. *Transfusion Medicine and Hemotherapy*
300 2021;48(3):137-47.
- 301 (18) Gross R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. Heterologous ChAdOx1 nCoV-
302 19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T
303 cell reactivity against prevalent SARS-CoV-2 variants. *EBioMedicine* 2021 Dec 17;75:103761.
- 304 (19) Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced
305 neutralizing breadth against SARS-CoV-2 one year after infection. *Nature* 2021 Jul;595(7867):426-
306 31.
307
308